1-17 of 17
Zhenfang Liu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001

Qian Jiang, Li Weiming, Yanli Zhang, Qiang Wang, Suning Chen, Bingcheng Liu, Zhuogang Liu, Jie Jin, Zhenfang Liu, Jianyu Weng, Xin Du, Xielan Zhao, Li Meng, Lie Lin, Wanlin Ye, Shujie Yan, Yihan Wang, Jingrong Cao
Journal: Blood
Blood (2024) 144 (Supplement 1): 477.
https://doi.org/10.1182/blood-2024-205300
Published: 2024
Journal Articles

A Phase 2 Study of Olverembatinib for the Treatment of Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement

Suning Chen, Depei Wu, Wenzhi CAI, Xueqing Dou, Zhenfang Liu, Yu Zhu, Ying Wang, Chunmei Yang, Jiong Hu, Miao Miao, Xiuzhi Deng, Chunyan Chen
Journal: Blood
Blood (2024) 144 (Supplement 1): 1781.
https://doi.org/10.1182/blood-2024-200003
Published: 2024
Journal Articles

Azacitidine, Venetoclax Combined with Chidamide (ABC-14 Regimen) As an Induction Therapy for Newly Diagnosed AML: A Real-World Retrospective Analysis By the ABC-14 Collaboration Group

Jianyu Weng, Chengxin Deng, Zhenqian Huang, Yuming Zhang, Wang Ying, Minming Li, Ping Wu, Honghua He, Xu Ye, Yirong Jiang, Min Dong, Zhenfang Liu, Xiaoliang Li, Runhui Zheng, Maoquan Zou, Lie Lin, Ying Zhao, Xiangzhong Zhang, Shuqin Cheng, Ziwen Guo, Xuejie Jiang, Zhilun Li, Jiaqi Tan, Chengwei Luo Luo, Suijing Wu, Peilong Lai, Yangqiu Li, Xin Huang, Xin Du
Journal: Blood
Blood (2024) 144 (Supplement 1): 6014.
https://doi.org/10.1182/blood-2024-210211
Published: 2024
Journal Articles

Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis

Xiaoshuai Zhang, Lu Yu, Li Zhou, Yanli Zhang, Huanling Zhu, Bingcheng Liu, Xin Du, Xiaodong Wang, Linhua Yang, Yanping Ma, Li Meng, Yanqing Zhang, Guohui Li, Lijie Yang, Baohong Wang, Xuehong Ran, Jian Huang, Qin Wen, Yan Wen, Yuxia Zhao, Yu Zhu, Yanqiu Han, Zhenfang Liu, Xin Du, Jianyu Weng, Qian Jiang
Journal: Blood
Blood (2024) 144 (Supplement 1): 4529.
https://doi.org/10.1182/blood-2024-203533
Published: 2024
Journal Articles

Olverembatinib-Based Therapy in Patients with Philadelphia Chromosome-Positive Acute Leukemia: A Multi-Centre Retrospective Study from China

Mei Bao, Jian Huang, Huiying Qiu, Suning Chen, Shengli Xue, Xiaofei Yang, Zhenfang Liu, Chunyan Chen, Linhua Yang, Yanping Ma, Li Meng, Yanli Zhang, Li Weiming, Qin Wen, Guohui Li, Lijie Yang, Yanqiu Han, Xiaodong Wang, Yan Wen, Congmeng Lin, Hai Yi, Xingli Zhao, Yanqing Zhang, Yang Song, Qian Jiang
Journal: Blood
Blood (2024) 144 (Supplement 1): 4528.
https://doi.org/10.1182/blood-2024-205232
Published: 2024
Journal Articles

Olverembatinib-Therapy in Patients with Accelerated-Phase Chronic Myeloid Leukaemia: A Multi-Centre Retrospective Study from China

Mengyao Yuan, Li Zhou, Xin Du, Jianyu Weng, Linhua Yang, Yanping Ma, Shasha Zhao, Zhenfang Liu, Qin Wen, Qingxian Bai, Xianqi Feng, Yanqiu Han, Aifang Li, Chunshui Liu, Qing Leng, Li Meng, Baohong Wang, Xuehong Ran, Xiaodong Wang, Haiguo Zhang, Yun Zeng, Yanli Zhang, Qian Jiang
Journal: Blood
Blood (2024) 144 (Supplement 1): 1767.
https://doi.org/10.1182/blood-2024-206453
Published: 2024
Journal Articles

Predictive Models for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Fang Cheng, Yu Wang, Xin Du, Yu Zhu, Jianyu Weng, Na Xu, Yunfan Yang, Jian Huang, Zhenfang Liu, Hongbo Ren, Huifang Zhao, Yajuan Ke, Weiyan Wu, Huanling Zhu, Qian Jiang, Yanli Zhang, Weiming Li
Journal: Blood
Blood (2024) 144 (Supplement 1): 4540.
https://doi.org/10.1182/blood-2024-202876
Published: 2024
Journal Articles

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Clinical Trials & Observations
Xiaoshuai Zhang, Bingcheng Liu, Jian Huang, Yanli Zhang, Na Xu, Robert Peter Gale, Weiming Li, Xiaoli Liu, Huanling Zhu, Ling Pan, Yunfan Yang, Hai Lin, Xin Du, Rong Liang, Chunyan Chen, Xiaodong Wang, Guohui Li, Zhuogang Liu, Yanqing Zhang, Zhenfang Liu, Jianda Hu, Chunshui Liu, Fei Li, Wei Yang, Li Meng, Yanqiu Han, Li’e Lin, Zhenyu Zhao, Chuanqing Tu, Caifeng Zheng, Yanliang Bai, Zeping Zhou, Suning Chen, Huiying Qiu, Lijie Yang, Xiuli Sun, Hui Sun, Li Zhou, Zelin Liu, Danyu Wang, Jianxin Guo, Liping Pang, Qingshu Zeng, Xiaohui Suo, Weihua Zhang, Yuanjun Zheng, Xiaojun Huang, Qian Jiang
Journal: Blood
Blood (2024) 144 (18): 1951–1961.
https://doi.org/10.1182/blood.2024024761
Published: 2024
Includes: Supplemental data
Journal Articles

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Suning Chen, Yanli Zhang, Na Xu, Hui Sun, Li Weiming, Yunfan Yang, Zunmin Zhu, Minghui Duan, Sixuan Qian, Yu Zhu, Jianmin Luo, Xiaodong Wang, Wei Yang, Weiying Gu, Fei Li, Bingcheng Liu, Yunxiao Xu, Zhenfang Liu, Chunling Wang, Yirong Jiang, Li Meng, Qin Wen, Yanli Xu, Xingli Zou, Wei Wang, Yan Xue, Hao Xu, Kehong Bi, Fuling Zhou, Liangming Ma, Rong Fu, Guifang Ouyang, Kaiyang Ding, Depei Wu
Journal: Blood
Blood (2023) 142 (Supplement 1): 1797.
https://doi.org/10.1182/blood-2023-179073
Published: 2023
Journal Articles

Flumatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: An Open-Label, Multi-Center Study

Ziyu Wen, Ying Zhao, Guowei Li, YongZhong Su, FeiHeng Chen, HongFang Tao, ZhengJin Zheng, Wuqiang Lin, XiuLi Chen, Meili Meng, Lian Yu, LongTian Chen, JianQing Huang, Guocai Wu, Mengxia Zhao, Zhenfang Liu, Hongqian Zhu, Yirong Jiang, Qifa Liu, Xiaoli Liu, Na Xu
Journal: Blood
Blood (2023) 142 (Supplement 1): 3175.
https://doi.org/10.1182/blood-2023-181456
Published: 2023
Journal Articles

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Qian Jiang, Zongru Li, Gongli Zhang, Yu Hu, Weiming Li, Yongping Song, Junmin Li, Li Zhou, Bingcheng Liu, Xiaoli Liu, Na Xu, Suning Chen, Zhenfang Liu, Huanling Zhu, Jie Jin, He Huang, Sixuan Qian, Li Meng, Xin Du, Xielan Zhao, Sujun Gao, Yang Liang, Ming Hou, Wei Wang, Zi Chen, Qian Niu, Lichuang Men, Dajun Yang, Yifan Zhai, Xiaojun Huang
Journal: Blood
Blood (2023) 142 (Supplement 1): 869.
https://doi.org/10.1182/blood-2023-187740
Published: 2023
Journal Articles

Safety and Efficacy of Tgrx-678, a Potent BCR-ABL Allosteric Inhibitor in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant/Refractory Chronic Myeloid Leukemia (CML): Preliminary Results of Phase I Study

Qian Jiang, Yanli Zhang, Qiang Wang, Jianyu Weng, Zhenfang Liu, Suning Chen, Li Weiming, Bingcheng Liu, Zhuogang Liu, Yihan Wang, Jingrong Cao
Journal: Blood
Blood (2023) 142 (Supplement 1): 867.
https://doi.org/10.1182/blood-2023-185977
Published: 2023
Journal Articles

Is the 2 nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study

Sen Yang, Xiaoshuai Zhang, Yanli Zhang, Xin Du, Jianyu Weng, Huanling Zhu, Ling Pan, Yun-fan Yang, Li Meng, Zhenfang Liu, Xiaoli Liu, Na Xu, Chunyan Chen, Xiaodong WANG, Rong Liang, Jian Huang, Guohui Li, Chunshui Liu, Hai Lin, Jianda Hu, Li Fei, Bingcheng Liu, Weiming Li, Zhuogang Liu, Wei Yang, Xiao Jun Huang, Qian Jiang
Journal: Blood
Blood (2022) 140 (Supplement 1): 815–817.
https://doi.org/10.1182/blood-2022-166855
Published: 2022
Journal Articles

Patient-Versus Physician-Perceptions of Symptoms, Treatment and Management in Chronic Myeloid Leukemia

Hong Chen, Yan Wen, Yun Zeng, LiE Lin, Xin Du, Zhenfang Liu, Bihong Sun, Hongqian Zhu, Huiqing He, Xiaotao Wang, Waiyi Zou, Caifeng Zheng, Liling Zheng, Jinxiong Huang, Liping Pang, Jixian Huang, Yuming Zhang, Haiqing Lin, Zelin Liu, Wanshou Zhu, Xuan Zhou, Qiang Wang, Xiaoli Liu, Qifa Liu, Na Xu
Journal: Blood
Blood (2022) 140 (Supplement 1): 10841–10842.
https://doi.org/10.1182/blood-2022-157246
Published: 2022
Journal Articles

Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia

Xiaoshuai Zhang, Bingcheng Liu, Jian Huang, Gongli Zhang, Xiaoli Liu, Na Xu, Weiming Li, Xin Du, Jianyu Weng, Hai Lin, Rong Liang, Chunyan Chen, Huanling Zhu, Ling Pan, Yunfan Yang, Xiaodong WANG, Guohui Li, Zhuogang Liu, Zhenfang Liu, Jianda Hu, Chunshui Liu, Li Fei, Wei Yang, Li Meng, Robert Peter Gale, Xiao Jun Huang, Qian Jiang
Journal: Blood
Blood (2022) 140 (Supplement 1): 9620–9623.
https://doi.org/10.1182/blood-2022-166431
Published: 2022
Journal Articles

A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy

Xiaoshuai Zhang, Bingcheng Liu, Jian Huang, Gongli Zhang, Xiaoli Liu, Na Xu, Weiming Li, Xin Du, Jianyu Weng, Hai Lin, Rong Liang, Chunyan Chen, Huanling Zhu, Ling Pan, Yun-fan Yang, Xiaodong WANG, Guohui Li, Zhuogang Liu, Zhenfang Liu, Jianda Hu, Chunshui Liu, Li Fei, Wei Yang, Li Meng, Robert Peter Gale, Xiao Jun Huang, Qian Jiang
Journal: Blood
Blood (2022) 140 (Supplement 1): 9637–9639.
https://doi.org/10.1182/blood-2022-168703
Published: 2022
Journal Articles

Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor

Xiaoshuai Zhang, Bingcheng Liu, Jian Huang, Gongli Zhang, Xiaoli Liu, Na Xu, Weiming Li, Xin Du, Jianyu Weng, Hai Lin, Rong Liang, Chunyan Chen, Huanling Zhu, Ling Pan, Yun-fan Yang, Xiaodong WANG, Guohui Li, Zhuogang Liu, Zhenfang Liu, Jianda Hu, Chunshui Liu, Li Fei, Wei Yang, Li Meng, Robert Peter Gale, Xiao Jun Huang, Qian Jiang
Journal: Blood
Blood (2022) 140 (Supplement 1): 3891–3894.
https://doi.org/10.1182/blood-2022-168812
Published: 2022